linjc16/ctgov huggingface dataset:
Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?

Study Overview
=================
Brief Summary
-----------------
Resident cells of human adipose tissue express ACE2 and DPP4, receptors for SARS-Cov2. The hypothesis is that the virus may enter and spread in fat depots.

Official Title
-----------------
Is Adipose Tissue a Reservoir for SARS-Cov2 Spread?

Conditions
-----------------
Covid-19 Patients

Intervention / Treatment
-----------------
* Procedure: biopsies of subcutaneous adipose tissue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female ≥ 18 years old Patients testing positive for Covid19 Patients affiliated to social security Signing of free and informed consent Exclusion Criteria: Vulnerable persons (- minors, adults under guardianship or curatorship, pregnant women, persons deprived of their liberty, persons who do not master the French language)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patients with Covid-19<br> | Procedure: biopsies of subcutaneous adipose tissue<br>* Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The presence of SARS-CoV2 in adipose tissue of Covid19 patients | RT-qPCR for SARS-Cov-2 from RNAs and by immunodetection | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The expression of inflammatory cytokines in adipose tissue of Covid19 patients | RT-qPCR for IL6 | Day 0 | 
| The expression of inflammatory cytokines in adipose tissue of Covid19 patients | RT-qPCR for IL1 | Day 0 | 
| The expression of inflammatory cytokines in adipose tissue of Covid19 patients | RT-qPCR for TNFa | Day 0 |
Prevalence of Urinary Incontinence in Different Age Categories

Study Overview
=================
Brief Summary
-----------------
Introduction: Urinary incontinence (UI) is considered erroneously by many as being a phenomenon of the aging process, however there is a growing prevalence of complaints of UI in nulliparous and nulligest young women. Objective: To investigate the prevalence of urinary incontinence in women of different age groups. Method: 78 nulliparous and nulligest women of different resident age groups in the city of France, being these divided in: G1 (10-18 years); G2 (20-35 years); G3 (45-60 years) and G4 (65-75 years). Excluded from this study were women with cancer or surgeries of the inferior urinary treatment, urinary infection, alterations cognitive, pregnant and obesity. All the participants were questioned as a perception of urine loss, to the efforts or effortlessly evident.

Detailed Description
-----------------
All participants were asked about perceived loss of urine, the effort or without apparent effort. The responses of participants from G1 were offered by parents and / or responsible.

Official Title
-----------------
Prevalence of the Urinary Incontinence in Adolescents, Young, Adults and Aged

Conditions
-----------------
Urinary Incontinence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: nulliparous and nulligest women Exclusion Criteria: women with cancer reported surgeries of the inferior urinary treatment urinary infection cognitive alterations pregnant obesity

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group I<br>10-18 years | |
| Group II<br>20-35 years | |
| Group III<br>45-60 years | |
| Group IV<br>65-75 years | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urinary Incontinence
Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate safety and pharmacokinetics of DW-0919 and DW-0920 in healthy male volunteers under fasting condition.

Official Title
-----------------
A Randomized, Open Label, 2-treatment, 2-sequence, Cross-over Study to Compare the Safety and Pharmacokinetics of DW-0919 and DW-0920 After Single Oral Administration in Healthy Male Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: DW-0920
* Drug: DW-0919


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult males aged 20 to 55 years at screening. No significant congenital/chronic disease. No symptoms in physical examination. Appropriate subjects as determined by past medical history, laboratory tests, serology and urinalysis. Be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the requirement of the study. Subject must provide written informed consent prior to study participation. Exclusion Criteria: History of Hyperreactivity with drug ingredients(acetaminophen, tramadol) or opioids. History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or cognitive disorders. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: DW-0919<br> | Drug: DW-0919<br>* Dosage form: Extended release tablet Dosage: 1 tablet<br>* Other names: Tramadol: 75mg;|
| Experimental: DW-0920<br> | Drug: DW-0920<br>* Dosage form: Extended release tablet Dosage: 2 tablets<br>* Other names: Wontran ER tab.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC of DW-0919(Acetaminophen, Tramadol) |  | 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 | 
| Cmax of DW-0919(Acetaminophen, Tramadol) |  | 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 | 
| AUC of DW-0920(Acetaminophen, Tramadol) |  | 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 | 
| Cmax of DW-0920(Acetaminophen, Tramadol) |  | 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36 |
Do we Prepare Patients for Their Digital Legacy? A Survey of Palliative Care Professionals in the West Midlands

Study Overview
=================
Brief Summary
-----------------
Conduct a questionnaire survey of palliative care professionals including doctors, nurses and social workers currently working within the West Midlands to establish how much the palliative care community in the West Midlands engage in preparing patients for their digital legacy and find out if there is a further education need in this community about digital legacy.

Official Title
-----------------
Do we Prepare Patients for Their Digital Legacy? A Survey of Palliative Care Professionals in the West Midlands

Conditions
-----------------
Death

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Palliative care professionals (medical, nursing and social worker) affiliated to a hospice in the West Midlands. Exclusion Criteria: Medical, nursing or social worker not working in a hospice in the West Midlands.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire|Questionnaire to be completed by staff|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Professionals' behaviour. | Questionnaire establishing a baseline measure from which to monitor changes over time in professionals' behaviour. | 6 weeks |
Ozone and Rhinovirus-Induced Disease in Asthmatics

Study Overview
=================
Brief Summary
-----------------
In the U.S., morbidity associated with human rhinovirus (RV) infection represents a major health problem. In asthmatics, up to 80% of asthma exacerbations are associated with upper respiratory infections. Despite evidence that environmental oxidant pollutants, such as ozone, may increase the severity of viral disease, the mechanisms underlying such an effect have not been identified. This study will test the hypothesis that exposure of allergic asthmatic subjects to ambient levels of ozone directly enhances viral disease by increasing infectivity and intensifying virus-induced inflammation.

Detailed Description
-----------------
In mild asthmatics, the study will investigate: (1) if exposure to ozone will enhance the viral infective process in the nasal epithelium, (2) the effect of ozone exposure on RV-induced inflammatory gene expression, mediator release and inflammatory cell influx into the upper and lower airways, and (3) the interactive effects of ozone and RV on airway reactivity. This information will improve our understanding of the risk associated with oxidant pollutant exposure in this population of individuals in whom RV infection may represent a significant health concern.

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Subjects recruited will be non-asthmatic controls or mild allergic asthmatics using beta-agonists, mostly on an as needed basis. Selection criteria will include good general health by medical history and physical examination, no history of smoking, and the absence of respiratory infection in the preceding 6 week period. Subjects will undergo serologic testing and must have a negative test for neutralizing antibodies to RV16 to participate in all but one study of the project.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Rhinovirus, Ozone
Validation of CardioQ Versus PiCCO in Children

Study Overview
=================
Brief Summary
-----------------
To compare the less invasive Oesophageal Doppler cardiac output Monitor (ODM) to the invasive (standard of care) Transpulmonary Thermodilution cardiac output monitor (TPTD) in children.

Detailed Description
-----------------
This is a validation study. The study period starts as soon as CMO approval is acquired and will end after inclusion of 17 patients. This study is designed to test the effectiveness of a non invasive ODM catheter compared to the invasive, gold standard, TPTD technique.

Official Title
-----------------
Validation of an Ultrasound Oesophageal Doppler Cardiac Output Monitor (ODM+, CardioQ) Versus a Transpulmonary Thermodilution Cardiac Output Monitor (TPTD, PiCCO)

Conditions
-----------------
Cardiac Output

Intervention / Treatment
-----------------
* Device: CardioQ


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 0 to 16 years with an indication for invasive CO monitoring (TPTD). Indication for invasive CO monitoring always implies intubation and sedation. Signed informed consent Exclusion Criteria: Congenital or acquired cardiovascular diseases (intracardiac/extracardiac intrathoracic shunt Cardiac valve diseases Aortic arch anomalies Tissue necrosis of oesophagus Carcinoma of pharynx, larynx of oesophagus Severe bleeding diatheses Age > 16 years Weight < 3.5 kg or > 50 kg.

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: children with an clinical indication for cardiac output monitoring in ICU or OR
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: CardioQ<br>CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor | Device: CardioQ<br>* comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously<br>* Other names: PiCCO;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac output | liter/m2/minute | 24 hours | 
| stroke volume | milliliters | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| flow time corrected | seconds | 24 hours | 
| stroke distance | centimeters | 24 hours |
ERAS in Liver Surgery

Study Overview
=================
Brief Summary
-----------------
Enhanced Recovery After Surgery (ERAS) Program (EP) is widely applied to obtain a reduction in post-operative length of hospital stay and a faster restoration of pre-operative patient conditions. However, in Western countries, adherence to EP in liver surgery is still difficult to achieve due to deep-rooted traditional practices. In our Institute, since 2019, EP has been applied pursuing 18/23 items identified by 2016 guidelines. At all consecutive patients who underwent elective liver surgery in our Institution, EP was proposed and their adherence to ERAS items was measured before, during and after surgery. Data were retrospectively collected and analysed, particularly focusing on EP items. Primary outcome was compliance to EP, defined as at least 80% of accomplished items per patient. Secondary outcome was adherence to each ERAS item, while tertiary outcome was detecting the variables associated with program drop out.

Official Title
-----------------
Enhanced Recovery After Surgery: Compliance to the Program in Liver Surgery and Factors Associated With Drop-out

Conditions
-----------------
ERAS

Intervention / Treatment
-----------------
* Procedure: Liver resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients candidates to surgery for benign or malignant liver disease liver resection with curative intent Exclusion Criteria: refusal to participate at the EP incapability to acquire informed consent cognitive impairment that can prejudice the patient comprehension of the EP liver surgery with palliative or diagnostic intent or non-resective liver surgery emergency surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ERAS-in<br>Patients who completed ERAS program | Procedure: Liver resection<br>* Liver resection, different kind of according to pathology<br>|
| ERAS-out<br>Patients who dropped-out from ERAS program | Procedure: Liver resection<br>* Liver resection, different kind of according to pathology<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance to ERAS program | Compliance to ERAS program was defined as at least 80% of accomplished items per patient | 32 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance to ERAS items | Compliance to each ERAS item singularly | 32 months | 
| Drop-out factors | Determining factors associated with ERAS program drop-out | 32 months |
Foley Catheter vs Double-balloon Catheter

Study Overview
=================
Brief Summary
-----------------
The efficiency of double-balloon and Foley catheters in the second trimester medical termination of pregnancies will be compared.

Detailed Description
-----------------
Women will be randomised into two groups. Foley catheter was applied to one group and double balloon catheter to the other group. After catheter expulsion or if the catheters did not spontaneously expulsed after 24 hours, i.v. oxytocin infusion will be started. Abortions will be considered successful if there will be no need of another method for abortion.

Official Title
-----------------
Comparison of Foley Catheter and Double-balloon Catheter in Second Trimester Pregnancy Termination

Conditions
-----------------
Pregnancy Termination, Catheter

Intervention / Treatment
-----------------
* Device: pregnancy termination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnancy termination, gestational age from 14-24 weeks Exclusion Criteria: multiple gestation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Foley catheter<br>Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved. | Device: pregnancy termination<br>* Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done<br>|
| Other: Double-balloon catheter<br>Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved. | Device: pregnancy termination<br>* Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| induction termination interval | time from induction to pregnancy termination | during procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
second trimester pregnancy termination, double-balloon catheter, foley catheter
A Pilot Study to Explore the Role of Gut Flora in Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Rheumatoid Arthritis

Detailed Description
-----------------
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding Rheumatoid Arthritis.

Official Title
-----------------
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study Male or female patients of any age (interest is given to children to compare with mothers). Diagnosis of Rheumatoid Arthritis Exclusion Criteria: Refusal to sign informed consent form History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. Postoperative stoma, ostomy, or ileoanal pouch Participation in any experimental drug protocol within the past 12 weeks Treatment with total parenteral nutrition Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Patients who have been diagnosed with Rheumatoid Arthritis | Other: No Intervention<br>* There is no intervention for this study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Microbiome to Disease via Relative Abundance and Presence of Absence of Specific Bacterial Species Found in Microbiome Sequencing | The identification of bacterial species residing the gut flora will be processed by next generation sequencing followed by metagenomic analysis. Bacterial diversity will then be evaluated in parallel with relative abundance of targeted species within and among individual microbes. For example, in examining the class clostridia looking at the species Clostridioides difficile and seeing what proportion of the Clostridia is represented by C. difficile. | One year |